Boston Scientific announced a definitive agreement to acquire Penumbra for about $14.5 billion, moving decisively into thrombectomy and embolization markets. The deal combines Boston Scientific’s broad cardiovascular portfolio with Penumbra’s clot-removal and embolization platforms, creating scale in high-growth acute vascular interventions. The acquisition is structured as a cash-and-stock transaction and targets expansion into fast-growing thrombectomy segments, including stroke and pulmonary embolism. Management says the deal will broaden procedural offerings for hospitals and ambulatory centers and accelerate Boston Scientific’s entry into complementary vascular categories. The transaction is expected to close in 2026 subject to customary approvals.